{
    "nct_id": "NCT03727750",
    "official_title": "A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG (TRADEMARKER)) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA",
    "inclusion_criteria": "Inclusion Criteria\n\n* Refractory or relapsed (ie, bone marrow blasts >5%) CD33-positive AML.\n* Age >=12 years.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2.\n* Initial peripheral white blood cells (WBC) counts >=30,000/mL; patients with a higher WBC count should undergo cytoreduction.\n* Adequate renal/hepatic functions\n\nExclusion Criteria\n\n* Patients with prior treatment with gemtuzumab ozogamicin (GO).\n* Patients with prior history of VOD/SOS.\n* Prior HSCT is not allowed, if it was conducted within 2 months prior to study enrollment.\n* Patients with known active central nervous system (CNS) leukemia.\n* Uncontrolled or active infectious status.\n* Uncontrolled cardiac dysrhythmias of NCI CTCAE Grade 2, uncontrolled atrial fibrillation of any grade.\n* Sero-positivity to human immunodeficieny virus (HIV).\n* Active hepatitis B or hepatitis C infection\n* Chemotherapy, radiotherapy, or other anti-cancer therapy (except hydroxyurea as cytoreduction) within 2 weeks prior to enrollment in the study.\n* Major surgery within 4 weeks prior to enrollment.\n* QTc interval >470 milliseconds (msec) using the Fridericia (QTcF), family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).\n* The use of medications known to predispose to Torsades de Pointes within 2 weeks prior to enrollment\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemtuzumab ozogamicin (GO).\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}